Asthma and COVID-19: What do we know now
- PMID: 33173369
- PMCID: PMC7588760
- DOI: 10.1177/1179548420966242
Asthma and COVID-19: What do we know now
Abstract
The COVID-19 pandemic has presented challenges in symptomology identification, diagnosis, management and follow-up in common respiratory diseases, and in particular asthma. Research is rapidly ongoing to try and understand how the SARS-CoV-2 virus affects individuals with asthma, as well as, how underlying asthma affects Covid-19 risk, symptomology and prognosis. In light of this unique medical challenge, clinicians are faced with case-by-case based decisions to implement or continue current asthma therapy. This review will discuss the current literature regarding asthma and COVID-19 based on best available evidence at this time (See box 1).
Keywords: COVID-19; asthma; biologics; corticosteroids; respiratory; treatment.
© The Author(s) 2020.
Conflict of interest statement
Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
References
-
- Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75:1730-1741. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous
